Modified bio-Bentall operation with a rapid deployment valve.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
3 patients (23.
I · Intervention 중재 / 시술
the modified bio-Bentall operation with an RDV between January 2018 and December 2022 was conducted
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Our initial experience with the modified bio-Bentall operation using an RDV shows favorable early outcomes in relatively high-risk patients. Further validation with larger datasets and long-term follow-up is needed to validate these results.
[OBJECTIVE] To evaluate the early outcomes of a modified bio-Bentall operation using a rapid deployment valve (RDV) in high-risk patients, focusing on procedural efficacy, survival rates, and complica
- 추적기간 35 months
APA
Park HK, Kim HR, Kim JB (2025). Modified bio-Bentall operation with a rapid deployment valve.. JTCVS techniques, 32, 47-52. https://doi.org/10.1016/j.xjtc.2025.04.003
MLA
Park HK, et al.. "Modified bio-Bentall operation with a rapid deployment valve.." JTCVS techniques, vol. 32, 2025, pp. 47-52.
PMID
40814651 ↗
Abstract 한글 요약
[OBJECTIVE] To evaluate the early outcomes of a modified bio-Bentall operation using a rapid deployment valve (RDV) in high-risk patients, focusing on procedural efficacy, survival rates, and complications.
[METHODS] A retrospective review of 11 consecutive patients who underwent the modified bio-Bentall operation with an RDV between January 2018 and December 2022 was conducted. Kaplan-Meier survival analysis was used to determine survival rates. Patients' baseline characteristics, operative details, and postoperative outcomes were reviewed.
[RESULTS] The median patient age was 71 years. Most patients presenting with high-risk conditions and significant comorbidities, including inflammatory conditions, chronic lung diseases, and advanced cardiac dysfunction. The median EuroSCORE II was 10.03%. The median aortic cross-clamping and cardiopulmonary bypass times were 73.0 minutes and 99.0 minutes, respectively. No early mortalities or reoperations occurred. Two patients (14.3%) required extracorporeal membrane oxygenation support because of low cardiac output and arrhythmias, and 3 patients (23.1%) required permanent pacemaker insertion. No paravalvular leakage or valve detachment was observed during follow-up. The 1-year survival rate was 90.9%, and the 3-year survival rate was 54.5%. Six patients died during a median follow-up of 35 months, from causes including respiratory complications, gastric cancer, and undetermined factors.
[CONCLUSIONS] Our initial experience with the modified bio-Bentall operation using an RDV shows favorable early outcomes in relatively high-risk patients. Further validation with larger datasets and long-term follow-up is needed to validate these results.
[METHODS] A retrospective review of 11 consecutive patients who underwent the modified bio-Bentall operation with an RDV between January 2018 and December 2022 was conducted. Kaplan-Meier survival analysis was used to determine survival rates. Patients' baseline characteristics, operative details, and postoperative outcomes were reviewed.
[RESULTS] The median patient age was 71 years. Most patients presenting with high-risk conditions and significant comorbidities, including inflammatory conditions, chronic lung diseases, and advanced cardiac dysfunction. The median EuroSCORE II was 10.03%. The median aortic cross-clamping and cardiopulmonary bypass times were 73.0 minutes and 99.0 minutes, respectively. No early mortalities or reoperations occurred. Two patients (14.3%) required extracorporeal membrane oxygenation support because of low cardiac output and arrhythmias, and 3 patients (23.1%) required permanent pacemaker insertion. No paravalvular leakage or valve detachment was observed during follow-up. The 1-year survival rate was 90.9%, and the 3-year survival rate was 54.5%. Six patients died during a median follow-up of 35 months, from causes including respiratory complications, gastric cancer, and undetermined factors.
[CONCLUSIONS] Our initial experience with the modified bio-Bentall operation using an RDV shows favorable early outcomes in relatively high-risk patients. Further validation with larger datasets and long-term follow-up is needed to validate these results.